There has been a worldwide increase in the numbers and complexity of cancer cases, alongside a predicted global shortage of pathologists. With this, classic manual analysis does not have the capability to support the precision medicine and drug development processes of the future.
Through its precision diagnostics platform, Aignostics turns complex biomedical data into transformative insights. It is able to power target identification (for drug development) and biomarker analyses, as well as support clinical trials with its toolkits.
The company plans to continue expanding its portfolio with new product offerings for biopharmaceutical clients. It is also leveraging its latest funding round to support growth in the US, as well as the development of leading foundation models for pathology in collaboration with Mayo Clinic.
Steph
Company Specialist at Welcome to the Jungle